FIL_MOZARTNCT06492837
Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Enrollment closed, study ongoing
- Trial sites reduced: 24 → 20 locations
- Minor Site details revised at 4 of 24 sitesv5
- Minor Site details revised at 13 of 24 sitesv4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 20 to 24
- Start date changed from estimate of Sep 15, 2024 to Oct 23, 2024
- Minor Study title shortened, about 2 wordsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (10)
Show 5 moreShow less
Arms and interventions
Pre-phase: Zanubrutinib 320 mg daily by mouth (D-15 to D-1) Induction phase cycle 1 (Q21 days): * Zanubrutinib 320 mg daily by mouth (D1-21) * Mosunetuzumab 5 mg, SC (D1) * Mosunetuzumab 45 mg, SC (D8) * Mosunetuzumab 45 mg, SC (D15) Induction phase cycles 2-12 (Q28 days): * Zanubrutinib 320 mg daily by mouth (D1-28) * Mosunetuzumab 45 mg, SC (D1) Maintenance phase cycles 13-24 (Q28 days): Zanubrutinib 320 mg daily by mouth (D1-28) Tocilizumab will be administered as needed to manage cytokine release syndrome (CRS) events.
Drugs: Mosunetuzumab in combination with Zanubrutinib
Sites
20 sites in 2 countries
Italy 16, Australia 4